VolitionRx Limited executes first supply and licensing contract for its Nu.Q Vet Cancer Screening Test in Asia
The contract is with Singapore-based SAGE Healthcare, a leading distributor of premium veterinary products and services in the region
Company
VolitionRx
NYSE:VNRX
VolitionRx Limited is a multi-national epigenetics company developing simple, easy-to-use, cost-effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients but also to improve their quality of life. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics. Volition's research and development activities are centered in Belgium, with additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market.
89 stories · page 3 of 5
VolitionRx well positioned with $22.9M as it shifts gears to become a commercial company with products
The company is in advanced negotiations with three top veterinary companies and anticipates signing a term sheet for Nu.Q Vet licensing and distribution with one of those parties before the end of 2021
VolitionRx strengthens balance sheet and closes 2Q with $27.9M in cash and cash equivalents
With a balance sheet of $19.4 million as of December 31, 2020, the company continues to manage expenditures carefully with a cash burn rate of about $2 million per month
VolitionRx says Nu.Q NETs assay shows promising results in coronavirus risk stratification
The company has been working with researchers at two NHS Foundation Trusts on coronavirus (COVID-19) studies for which abstracts were released this week
VolitionRx unveils robust balance sheet, progression of its Nu.Q products ahead of US launch in 1Q update
During the quarter, Volition initiated production of Nu.Q product components at scale at its Silver One manufacturing facility in Isnes, Belgium
VolitionRx Limited sees Nu.Q Capture assay paper published in scientific journal
The NuQ platform looks for molecular signatures of cancer by focusing on the nucleosomes — a section of DNA wrapped around a core of proteins — in the blood
VolitionRx appoints industry veterans Kim Nguyen and Richard Brudnick to its board of directors
Nguyen is currently serving as Head of Human Resources for Google Asia Pacific, while Brudnick has held senior positions in a number of pharmaceutical companies
VolitionRx CEO says company in ‘strongest-ever financial position’ to pursue ‘many milestones’
Following a public offering in February, the firm’s cash and equivalents totaled $40 million before deducting expenses incurred so far in 2021
VolitionRx says new data demonstrate Nu.Q's effectiveness in monitoring treatment of Sepsis
The company said an abstract on the findings has been released at a virtual meeting of the International Society for Apheresis
Small-Cap Snapshot: JinkoSolar shares fall after second-quarter earnings miss
VolitionRx shares advance on promising test accuracy for prostate cancer
VolitionRx commences first triage study in Asia, gets ethical approval for final phase of a study in Denmark
The NYSE-listed firm said it has begun an evaluation of its Nu.QTM Colorectal Cancer Triage product in a Taiwanese population of 383 subjects
VolitionRx eyeing launch in Europe of colorectal cancer test next year
The CE Mark will make the blood test potentially saleable in all 28 EU countries.
VolitionRx Ltd set for US$10.6mln cash boost after placing
In September, VolitionRx said it expects to receive European Union CE Marking on its Nu. Q colorectal cancer blood test later this year.
VolitionRx readies for first product launch
A first NuQ blood test will be launched for colorectal cancer later this year in Europe
VolitionRx eyes commercialisation of first cancer test
Chief executive Cameron Reynolds told Proactive: "It's one thing to be a science project. It's another to have products and we are right on the cusp of that.”
VolitionRx gearing up with NUQ market entry with new hire
Cancer diagnostics group VolitionRx Ltd is gearing up for the initial market entry of its NuQ blood tests with the appointment of an experienced marketing executive.
VolitionRx Ltd delighted with European approval for two blood assays
Cancer diagnostics and life sciences group VolitionRx Ltd reached yet another milestone - with the award of CE marks for two of its blood-based tests for detecting colorectal cancer.
VolitionRx Limited raises around US$12.8mln from share offer
Cancer diagnostics group VolitionRx Limited has raised around US$12.8mln from its share placing, which will be used to further the business, including for clinical studies and product commercialisation.
VolitionRx to raise US$12.25mln at modest discount
The company is currently going through the approval process for a European CE mark
VolitionRx pleased with progress in 2015
The NuQ test measures nucleosomes in the bloodstream – an indication that cancer is present.